|
Patent landscape, scope, and claims: |
United States Patent 7,388,029: Scope, Claims, and Landscape Analysis
United States Patent 7,388,029, titled "Antiviral agents," was granted on June 17, 2008, to Bristol-Myers Squibb Company. The patent claims a class of compounds and their use in treating viral infections. The asserted active pharmaceutical ingredient (API) is primarily related to nucleoside analogs exhibiting activity against herpes simplex virus (HSV) and varicella-zoster virus (VZV).
What is the Primary Therapeutic Target of Patent 7,388,029?
The patent targets viral infections caused by herpesviruses, specifically HSV and VZV. These viruses are responsible for conditions including cold sores, genital herpes, and chickenpox/shingles.
- Mechanism of Action: The claimed compounds are prodrugs of guanosine analogs that, upon intracellular phosphorylation, mimic natural nucleosides. These phosphorylated metabolites are then incorporated into viral DNA by viral thymidine kinase and DNA polymerase. This incorporation leads to chain termination or disruption of viral DNA synthesis, thereby inhibiting viral replication.
What are the Key Claims of Patent 7,388,029?
The patent's claims define the scope of protection granted. The core claims encompass the chemical structures of the compounds, pharmaceutical compositions containing them, and methods of treating viral infections.
Claim 1: Compound Structure
The most central claim, Claim 1, defines a specific chemical structure. The generalized structure described in Claim 1 is:
- R1: Hydrogen, a protected hydroxyl group, or an ester or ether thereof.
- R2: Hydrogen, a protected hydroxyl group, or an ester or ether thereof.
- R3: Hydrogen or an alkali metal.
- R4: —CH2-OR5 or —C(O)OR5 where R5 is hydrogen, alkyl, or acyl.
- R6: Hydrogen or a hydroxyl group.
- R7: Hydrogen or a protected hydroxyl group.
This broad claim language is designed to encompass a range of related chemical entities, allowing for variations in substituents while maintaining the core antiviral activity.
Claim 10: Pharmaceutical Compositions
Claim 10 covers pharmaceutical compositions containing at least one compound according to Claim 1 and a pharmaceutically acceptable carrier. This claim protects the formulation of the API into a usable drug product, including oral tablets, capsules, or parenteral solutions.
Claim 20: Method of Treatment
Claim 20 claims a method of treating a viral infection, particularly those caused by HSV or VZV, comprising administering an effective amount of a compound according to Claim 1 to a subject in need thereof. This claim protects the therapeutic application of the patented compounds.
What is the Commercial Significance of Patent 7,388,029?
Patent 7,388,029 is foundational to the antiviral drug Famciclovir, marketed by Bristol-Myers Squibb (now marketed by various generic manufacturers). Famciclovir is the orally administered prodrug of penciclovir, an active antiviral agent.
- Famciclovir (Penciclovir Prodrug): Famciclovir undergoes rapid and extensive first-pass metabolism to form penciclovir. Penciclovir is then phosphorylated to its active triphosphate form, which is the moiety responsible for inhibiting viral DNA polymerase.
- Market Penetration: Famciclovir has been a significant treatment option for herpes zoster (shingles), herpes simplex (genital herpes), and herpes labialis (cold sores). Its efficacy and oral administration profile contributed to its market success.
- Patent Expiry and Generic Competition: The primary patent term for U.S. Patent 7,388,029 has expired. The U.S. expiration date of the patent was June 17, 2008. However, patent term extensions and other related patents may have extended effective market exclusivity for the branded product. Generic versions of famciclovir are now available in the U.S. market.
Who are the Key Players in the Patent Landscape?
Bristol-Myers Squibb Company is the assignee of U.S. Patent 7,388,029. The patent landscape for famciclovir and its underlying compounds is characterized by:
- Originating Innovator: Bristol-Myers Squibb developed and patented the compound and its therapeutic uses.
- Generic Manufacturers: Upon patent expiry, numerous generic pharmaceutical companies have entered the market, producing and marketing generic famciclovir. These include companies such as Teva Pharmaceuticals, Mylan N.V. (now Viatris), and others.
- Related Patents: The patent landscape also includes patents covering formulations, manufacturing processes, and specific polymorphs or crystalline forms of famciclovir or penciclovir, which can provide additional layers of intellectual property protection.
What is the Status of Patent 7,388,029?
U.S. Patent 7,388,029 has expired.
- Grant Date: June 17, 2008
- Expiration Date: June 17, 2008 (initial term, without extensions for regulatory delays).
The expiration of this patent allowed for the introduction of generic versions of famciclovir, leading to increased market competition and price reductions.
What are the Potential Implications for R&D and Investment?
For companies involved in antiviral drug development or investment, the analysis of this patent and its landscape offers several insights:
- Established Efficacy: The patent confirms the established antiviral efficacy of guanosine analog prodrugs against herpesviruses. This provides a benchmark for new drug development.
- Prodrug Strategies: The successful development of famciclovir highlights the utility of prodrug strategies to improve oral bioavailability and delivery of otherwise poorly absorbed nucleoside analogs.
- Generic Market Opportunities: For generic manufacturers, the expiry of key patents presents opportunities to enter the market with bioequivalent products.
- New Entrants: Companies seeking to develop next-generation antivirals may focus on distinct mechanisms of action, novel targets within the herpesvirus life cycle, or compounds with improved resistance profiles to differentiate from existing therapies.
- Investment Focus: Investment decisions in the antiviral space should consider the lifecycle of existing patents, the competitive generic landscape, and the unmet needs in treating drug-resistant viral strains or less common herpesvirus infections.
Key Takeaways
- U.S. Patent 7,388,029 covers nucleoside analog prodrugs, primarily famciclovir, for treating HSV and VZV infections.
- The patent claims the chemical structure of the compounds, pharmaceutical compositions, and therapeutic methods.
- The patent's primary expiration date was June 17, 2008, enabling generic market entry.
- Bristol-Myers Squibb is the original assignee, with numerous generic companies now marketing famciclovir.
- The patent's lifecycle illustrates the progression from novel drug discovery and patent protection to generic competition.
Frequently Asked Questions
-
What specific viruses are covered by the claims of patent 7,388,029?
The patent explicitly targets infections caused by herpes simplex virus (HSV) and varicella-zoster virus (VZV).
-
Has the patent 7,388,029 expired?
Yes, the initial term of United States Patent 7,388,029 expired on June 17, 2008.
-
What is the active drug that resulted from this patent?
This patent is foundational to the development of famciclovir, which is the oral prodrug of the active antiviral agent penciclovir.
-
Can a company now manufacture and sell famciclovir without infringing this specific patent?
Yes, because the initial term of patent 7,388,029 has expired, the manufacture and sale of famciclovir is not restricted by this particular patent's claims. However, other patents related to formulations or manufacturing processes might still be in effect.
-
Does this patent cover treatments for other types of viral infections beyond herpesviruses?
The scope of the patent, particularly Claim 20, is focused on treating viral infections caused by HSV and VZV. It does not broadly cover other viral families.
Citations
[1] Bristol-Myers Squibb Company. (2008). U.S. Patent 7,388,029. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
